Banque Transatlantique SA Invests $2.68 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Banque Transatlantique SA bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,491 shares of the company's stock, valued at approximately $2,681,000.

Other hedge funds have also made changes to their positions in the company. Hurley Capital LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. boosted its holdings in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IDXX shares. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Morgan Stanley increased their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $524.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded up $0.80 during trading hours on Friday, hitting $490.78. 326,191 shares of the stock were exchanged, compared to its average volume of 647,571. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $548.88. The business's 50-day moving average is $422.31 and its two-hundred day moving average is $429.15. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market capitalization of $39.77 billion, a P/E ratio of 46.00, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the prior year, the company earned $2.71 EPS. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.